Tysabri, by contrast, will probably never face true generic competition, because it is a type of drug called a monoclonal antibody that will be much harder to produce cheaply.
Mutual, however, argues that federal law preempts this type of claim, because the FDA had already approved its drug and federal law also requires a generic drug to have the same design as the brand-name medication ( here is the petition).